Medicines Company To Undertake Two Hirulog Studies After Cmte. Rejection
Executive Summary
The Medicines Company is prepared to go ahead with two previously planned studies for Hirulog (bivalirudin) following an FDA advisory committee rejection of the anticoagulant.